CBM light up lives mid banner advert
Advertisement: Hewitsons mid banner
Advertisement: Kao Data Centre mid banner
ARM Innovation Hub
Advertisement: Simpsons Creative
Mid banner advertisement: BDO
Advertisement – Charles Stanley mid banner
Advertisement: Cambridge Network mid banner
Advertisement: CJBS mid banner
Advertisement: Howard Group mid banner
Advertisement: EY Mid banner
Advertisement: Mogrify mid banner
Advertisement mid banner S-Tech 1
Advertisement: RSM
Barr Ellison Solicitors – commercial property
Advertisement: EBCam mid banner
11 March, 2021 - 13:04 By Tony Quested

Sosei earns $2.5 milestone after Formosa’s US success

Sosei Group Corporation, whose R & D heartland is in Cambridge, has clinched a $2.5 million milestone payment from its deal with Formosa Pharmaceuticals Inc.

It stems from Formosa Pharmaceuticals dosing the first patient in a 370-patient randomised Phase 3 clinical trial of APP13007 in the United States. APP13007 is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery.
 
It was originally designed and developed at Activus Pharma Inc. formerly a wholly owned subsidiary of the company. Activus was divested in August 2017 to Formosa, a wholly owned subsidiary of Formosa Laboratories, Inc., a leading manufacturer of Active Pharmaceutical Ingredients listed on the Taiwan Stock Exchange. 

The divestment was part of Sosei Heptares’ redirected growth strategy towards the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities.

Activus was originally developing APP13007 by applying its patented proprietary APNT (Activus Pure Nanoparticle Technology) to the steroid to create a novel nanoparticle formulation for treating post-operative inflammation of the eye. 

Since the divestment, Formosa has progressed the development of APP13007 and is now aiming to begin Phase 3 trials in the United States imminently.

Under the terms of the sale to Formosa in 2017, Sosei Heptares is entitled to receive undisclosed milestone payments based on progression of Activus’ pipeline as well as royalties from the commercialisation of certain products should they reach the market.

Shinichi Tamura, chairman, president and CEO of Sosei Heptares, said: “It is great to see the progress that Formosa has made advancing the development of APP13007. Entering Phase 3 trials is a fantastic achievement.”

Newsletter Subscription

Stay informed of the latest news and features